SCHEMBL7998726

SCHEMBL7998726

Cc1ccc(-c2nc3ccc(C)cn3c2C(C)C)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.56
NR1H4 Q96RI1 6/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.49
GABRA1 P14867 2/20 0.49
GABRB2 P47870 2/20 0.49
LMNA P02545 1/20 0.49
ALB P02768 1/20 0.49
CYP3A4 P08684 1/20 0.49
CHRM1 P11229 1/20 0.49
GABRB1 P18505 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA3 P34903 1/20 0.49
ADRA1A P35348 1/20 0.49
OPRK1 P41145 1/20 0.49
HTR2B P41595 1/20 0.49
GABRA2 P47869 1/20 0.49
KCNH2 Q12809 1/20 0.49
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723542 0.85 TP53 (0.51) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL6216568 0.83 KDM4E (0.52) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL6216380 0.81 KDM4E (0.50) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL1692153 0.80 TP53 (0.55) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL6011806 0.80 KDM4E (0.52) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL5253722 0.80 KDM4E (0.52) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL13177316 0.80 TP53 (0.62) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL20356291 0.80 COMT (0.46) TP53NR1H4KDM4EGAAMAPT
SCHEMBL2222633 0.79 TP53 (0.45) TP53NR1H4KDM4EHPGDGABRA1
SCHEMBL12410692 0.79 TP53 (0.45) TP53NR1H4KDM4EHPGDGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed
WO-2009143156-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SEPRACOR INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD TP53 1791/4885NR1H4 674/4885KDM4E 3088/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD TP53 1791/4885NR1H4 674/4885KDM4E 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.